比较培美曲塞与多西他赛分别联合顺铂治疗非小细胞肺癌的疗效及安全性分析  

Comparative Efficacy and Safety Analysis of Pemetrexed and Docetaxel Combined with Cisplatin in Non-small Cell Lung Cancer

作　　者：韦雪丽 汪艳娟[1] 米聪 WEI Xue-li;WANG Yan-juan;MI Cong(Shangqiu First People's Hospital,Shangqiu 476000,Henan Province,China)

机构地区：[1]商丘市第一人民医院,河南商丘476000

出　　处：《罕少疾病杂志》2024年第11期48-50,共3页Journal of Rare and Uncommon Diseases

基　　金：河南省医学科技攻关计划(联合共建)项目(LHGJ20190911)。

摘　　要：目的本项研究旨在探究培美曲塞联合顺铂与多西他赛联合顺铂在治疗非小细胞肺癌方面的疗效及安全性。方法本研究纳入了2020年2月至2022年3月期间在我院接受治疗的80名非小细胞肺癌患者。通过随机数字表法,这些患者被平均分配到两个治疗组,每组40人。其中一组患者接受了以顺铂和多西他赛为基础的化疗方案作为对照组,而另一组则接受了顺铂和培美曲塞的联合治疗作为观察组。研究中,我们对比了两组患者在治疗结束后的疗效,并监测了他们在治疗开始和结束时血液中癌胚抗原(CEA)及糖类抗原125(CA125)的浓度变化。统计患者治疗过程中不良反应发生率。比较患者1年生存率与无病生存时间的差异。结果观察组显效患者为有效治疗率显著高于对照组患者(P=0.025)。观察组患者治疗后CEA与CA-125水平下降程度要高于对照组患者(P<0.0001)。对照组患者皮肤反应和消化道反应与观察组患者相比无差异(P>0.05)。但是对照组患者骨髓抑制发生率显著高于观察组患者,存在统计学差异(P=0.045)。两组患者1年生存率与无病生存时间均无差异(P>0.05)。结论对于晚期NSCLC患者,培美曲塞和顺铂的联合治疗在改善预后上优于多西他赛和顺铂的联合治疗,并且还可以减少患者不良反应的发生。Objective The aim of this study is to compare the efficacy and safety of pemetrexed versus docetaxel,each in combination with cisplatin,in the treatment of non-small cell lung cancer.Methods A total of 80 patients with mycoplasma pneumonia who were treated in our hospital from February 2020 to March 2022 were selected as the research subjects.The patients were randomly assigned to a control group and an observation group,with 40 patients in each group,according to a random number table.The control group received cisplatin+docetaxel treatment,while the observation group was treated with pemetrexed+cisplatin.The clinical efficacy after treatment in the two groups was compared,and changes in serum carcinoembryonic antigen(CEA)and carbohydrate antigen 125(CA-125)before and after treatment were observed.The incidence of adverse reactions during treatment was recorded,and the difference in 1-year survival rate and disease-free survival time was compared.Results The observation group exhibited a significantly higher effective treatment rate compared to the control group(P=0.025).Additionally,the post-treatment reduction in CEA and CA-125 levels was significantly greater in the observation group than in the control group(P<0.0001).There was no difference in skin reactions and gastrointestinal reactions between the control and observation groups(P>0.05).However,the incidence of bone marrow suppression was significantly higher in the control group compared to the observation group,with a statistically significant difference(P=0.045).There was no difference in the 1-year survival rate and disease-free survival time between the two groups(P>0.05).Conclusion For patients with advanced NSCLC,the combination of pemetrexed and cisplatin is superior to the combination of docetaxel and cisplatin in improving prognosis,and it can also reduce the occurrence of adverse reactions in patients.

关 键 词：培美曲塞 多西他赛 顺铂 非小细胞肺癌 疗效 安全性 

分 类 号：R322.35[医药卫生—人体解剖和组织胚胎学]